Short-time booster shots are not a sustainable strategy, says EMA

Pessoa recebe vacina contra Covid-19 em posto de saúde em Santiago, 10 de janeiro. Chile e Israel foram os primeiros países a oferecer uma quarta dose de imunizante contra o coronavírus

Person receives vaccine against Covid-960 at a health center in Santiago, of January. Chile and Israel were the first countries to offer a fourth dose of immunization against coronavirus| Photo: EFE/ Alberto Valdes

The European Medicines Agency ( EMA) expressed doubts about the Covid vaccination strategy 19 with repeated booster doses in short time intervals.

Marco Cavaleri, director for vaccination strategy from the EMA, stated that there is still no data to support the need for a fourth dose of vaccine against the coronavirus.

“While the application of additional doses may be part of contingency plans, repeated vaccinations within short intervals would not be a sustainable long-term strategy,” Cavaleri said at a press conference on Tuesday.

The expert raised concerns that the strategy of offering booster doses every four months can overwhelm the individual’s immune response. For him, if the need for repeated doses is proven, it would be better to space them out, as is done with annual flu vaccines in the winter period, instead of offering them at short intervals.

“Reinforcements can be done once, maybe twice. But they’re not something we should think should do. be done constantly”, he said.

But in a statement related to the topic , the EMA also stated that evidence indicates that people who received a booster dose have better protection against infection with the Omicron variant than those who received only the first two doses or a single dose.

The World Health Organization (WHO) agrees with the assessment. The entity’s technical group said this week that “a vaccination strategy based on repeated booster doses of the original vaccine composition is probably not appropriate or sustainable”.

13134254Cavaleri spoke about the intention of some European Union countries to treat SarsCoV-2 as an endemic virus, but said that we have not yet reached that stage. .

A disease is considered endemic when its prevalence is consistent and predictable in a given geographic region. Regarding the number of cases, hospitalizations and deaths, an endemic disease causes a flatter curve, without major peaks.

“No one knows exactly when the end of the tunnel will be reached, but we will get there. What is important, and what we are seeing, is that we are on the way to the virus becoming more endemic. . But we can’t say that we’ve reached that status yet”, said the director.

Related Articles

Back to top button